Hims & Hers Health Inc (NYSE:NVO) shares are higher Wednesday morning after a series of announcements this week reinforced investor optimism around the company’s weight-loss strategy and broader platform expansion. Here’s what investors need to know.
- Hims & Hers Health stock is surging to new heights today. What’s driving HIMS stock higher?
Novo Nordisk Partnership Brings Ozempic, Wegovy To Hims Platform
The biggest catalyst was a new partnership with Novo Nordisk A/S (NYSE:NVO) that will bring branded GLP-1 treatments including Ozempic and Wegovy to the Hims & Hers platform later this month, while also ending Novo’s lawsuit against the telehealth company. That removes a legal overhang and signals a more collaborative relationship with a major drugmaker.
Hims & Hers also said it is shifting its U.S. weight-loss business away from actively advertising compounded GLP-1 drugs and toward a wider assortment of FDA-approved treatments.
Existing patients may transition to branded therapies when providers determine that is clinically appropriate, while compounded offerings are expected to remain available only on a limited basis for select cases.
Analysts Upgrade HIMS Stock After NVO Partnership
Analyst sentiment improved after the Novo announcement. Citigroup upgraded the stock to Neutral from Sell and lifted its price target to $24 from $13.25, while Bank of America also upgraded shares to Neutral and raised its target to $23 from $12.50.
Hims Expands Wellness Platform With New Member Perks
Separately, Hims & Hers launched a new subscriber benefits program offering discounts on services and products from partners including Prenuvo and Eight Sleep, broadening its wellness ecosystem beyond prescriptions alone.
Hims Stock Rebounds After Steep Multi-Month Decline
Hims & Hers stock has been in a broad downtrend from its late-summer peak of $66.18, falling below its 20-day, 50-day and 200-day moving averages before a sharp rebound this week.
Even with that bounce, the shares remain well off their highs, suggesting the longer-term trend is still weak.
Benzinga Edge Rankings
According to Benzinga Edge rankings, Hims & Hers Health Inc. shows a Growth score of 56.09 but a weak Momentum score of 1.23, highlighting strong expansion metrics despite poor recent trading momentum.
Hims Shares Climb Wednesday Morning
HIMS Price Action: Hims & Hers Health shares were up 12.78% at $26.47 at the time of publication on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
Recent Comments